Nathan, PaulPaulNathanZweifel, MartinMartinZweifelPadhani, Anwar RAnwar RPadhaniKoh, Dow-MuDow-MuKohNg, MatthewMatthewNgCollins, David JDavid JCollinsHarris, AdrianAdrianHarrisCarden, CraigCraigCardenSmythe, JonJonSmytheFisher, NitaNitaFisherTaylor, N JaneN JaneTaylorStirling, J JamesJ JamesStirlingLu, Shiao-PingShiao-PingLuLeach, Martin OMartin OLeachRustin, Gordon J SGordon J SRustinJudson, IanIanJudson2024-10-112024-10-112012https://boris-portal.unibe.ch/handle/20.500.12422/84352The vascular disrupting agent (VDA) combretastatin A4 phosphate (CA4P) induces significant tumor necrosis as a single agent. Preclinical models have shown that the addition of an anti-VEGF antibody to a VDA attenuates the revascularization of the surviving tumor rim and thus significantly increases antitumor activity.enarticle2264505200030750210002310.1158/1078-0432.CCR-11-3376